NCT00041795已完成2 期
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Neotrofin to Treat Patients With Sensory or Motor Neuropathy Caused by Chemotherapy for Cancer
NeoTherapeutics11 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2002年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 11
研究概览
简要总结
This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy.
- •Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at baseline.
- •In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable.
- •Patient must have normal hematological cell counts.
- •Patient must have a life expectancy of >/= 3 months.
排除标准
- 未提供
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
Treatment of Peripheral Neuropathy in Patients With DiabetesDiabetic NeuropathiesDiabetes MellitusNCT00044421Eli Lilly and Company400
已完成
不适用
Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder SymptomsOveractive BladderNCT04999657Medtecx Co Ltd.109
已完成
2 期
Neurotropin Treatment of FibromyalgiaFibromyalgiaNCT00366535National Institute of Nursing Research (NINR)56
终止
1 期
SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)Chemotherapy-induced Peripheral Neuropathy (CIPN)NCT05435742Sonnet BioTherapeutics9
招募中
2 期
Randomized controlled trial for peripheral neuropathy comparing weekly Paclitaxel followed by FEC100 with Eribulin Mesilate followed by FEC100 as neoadjuvant chemotherapy in primary breast cancer patients.Operable early Breast CancerJPRN-UMIN000012817JONIE Study Group230